Matinas Biopharma Holdings, Inc. Common Stock (MTNB)
Frequently Asked Questions About Matinas Biopharma Holdings, Inc. Common Stock (MTNB)
How can investors stay updated on Matinas Biopharma?
Investors can stay updated on Matinas Biopharma by following official communications such as press releases, earnings reports, and investor presentations available on the company’s website. Additionally, financial news platforms and brokerage accounts typically provide updates on stock performance and significant company announcements.
How does Matinas Biopharma ensure the safety and efficacy of its products?
Matinas Biopharma ensures the safety and efficacy of its products through rigorous clinical trial protocols that comply with regulatory standards set by the FDA and other governing bodies. This process involves conducting Phase I, II, and III trials to comprehensively evaluate the pharmacokinetics, pharmacodynamics, safety, and overall effectiveness of its drug candidates.
How does Matinas Biopharma's technology benefit patients?
Matinas Biopharma’s technology benefits patients by potentially improving the efficacy and bioavailability of medications that can be difficult to absorb through conventional means. This enhanced delivery can lead to better treatment adherence, quicker onset of therapeutic effects, and potentially improved outcomes in patients who require ongoing therapy.
How is Matinas Biopharma funded?
Matinas Biopharma is funded through a combination of public capital raised in its IPO, private placements, and research grants. The company also monitors partnerships and licensing agreements that can bring additional funding to support its clinical programs and operational activities.
On which stock exchange is Matinas Biopharma listed?
Matinas Biopharma Holdings, Inc. is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol MTNB. Being listed on a major exchange provides the company with increased visibility and access to capital markets.
What are Matinas Biopharma's target markets?
The target markets for Matinas Biopharma include therapeutics for infectious diseases and rare diseases, which represent significant unmet medical needs. The company aims to provide innovative treatment options in these areas, where traditional therapies may not be effective or available, thus addressing significant gaps in patient care.
What are the potential competitive advantages of Matinas Biopharma?
Matinas Biopharma's competitive advantages include its innovative MAT9001 delivery platform, which could significantly improve the bioavailability of therapeutics, potentially enhancing treatment outcomes for patients. Additionally, the company's experienced leadership and focus on niche markets may differentiate it from competitors in the biopharmaceutical sector.
What clinical trials is Matinas currently conducting?
Matinas Biopharma is conducting several clinical trials aimed at assessing the safety and efficacy of its drug candidates. These include trials related to MAT9001 and other investigational products targeting specific infections and rare disease indications, with ongoing evaluations to fulfill regulatory requirements.
What does Matinas Biopharma Holdings, Inc. do?
Matinas Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of infectious diseases and rare diseases. The company utilizes its proprietary delivery platform, known as MAT9001, to enhance the bioavailability of existing drugs and to deliver novel therapeutics more effectively.
What impact does regulatory approval have on Matinas Biopharma?
Regulatory approval is crucial for Matinas Biopharma, as it determines the company's ability to market and sell its drug products. Securing clearance from the FDA allows the company to move forward with commercializing its offerings, while also enhancing credibility with investors and partners, leading to potential increases in stock value.
What is MAT9001?
MAT9001 is Matinas Biopharma's proprietary drug delivery technology designed to improve the bioavailability and convenience of orally administered therapies. This technology can encapsulate drugs in a lipid-based delivery system, enhancing absorption and potentially leading to better patient outcomes and compliance.
What is Matinas Biopharma's business model?
Matinas Biopharma's business model centers around the development of proprietary drug delivery technologies and conducting clinical trials. The company may also explore partnerships and collaborations with larger biopharmaceutical companies to co-develop or license its technologies and drug candidates, allowing for shared risk and potential financial returns.
What is Matinas Biopharma's vision for the future?
Matinas Biopharma envisions becoming a leader in the biopharmaceutical space by advancing innovative solutions for treating complex diseases. The company aims to grow its portfolio of effective therapies while expanding its research capabilities and maintaining a patient-centered focus throughout its operations.
What is the current status of Matinas Biopharma's drug pipeline?
As of the latest updates, Matinas Biopharma has a diverse drug pipeline that includes candidates in various stages of clinical development. The company regularly provides updates on the progress of its clinical trials and the advancement of its drug candidates, highlighting results and findings as they become available.
What is the focus of Matinas Biopharma's research?
The focus of Matinas Biopharma's research is primarily on developing treatments for infectious diseases and rare disease conditions. The company aims to leverage its proprietary delivery technology to enhance existing therapeutic options and to advance new drug candidates through clinical trials.
Where is Matinas Biopharma located?
Matinas Biopharma is headquartered in Bedminster, New Jersey. The location allows the company to be strategically positioned within a hub of biopharmaceutical innovation, providing access to important resources, partners, and industry networks.
Who are Matinas Biopharma's main partners or collaborators?
Matinas Biopharma collaborates with various research institutions, universities, and pharmaceutical partners to facilitate the development of its technologies and drug candidates. These partnerships may involve joint research efforts, funding arrangements, and shared access to specialized resources, which can accelerate product development.
Who are the key executives at Matinas Biopharma?
Matinas Biopharma is led by a team of experienced executives, including Chief Executive Officer Jerome D. Hauer and Chief Financial Officer Kevin G. Kauffman. The executive team brings extensive backgrounds in biopharmaceuticals, corporate strategy, and finance, positioning the company for growth and success in the competitive biotech landscape.
What is the current price of Matinas Biopharma Holdings, Inc. Common Stock?
The current price of Matinas Biopharma Holdings, Inc. Common Stock is 0.3320
When was Matinas Biopharma Holdings, Inc. Common Stock last traded?
The last trade of Matinas Biopharma Holdings, Inc. Common Stock was at 8:00 pm EDT on July 27th, 2026
What is the market capitalization of Matinas Biopharma Holdings, Inc. Common Stock?
The market capitalization of Matinas Biopharma Holdings, Inc. Common Stock is 2.13M
How many shares of Matinas Biopharma Holdings, Inc. Common Stock are outstanding?
Matinas Biopharma Holdings, Inc. Common Stock has 6.41M shares outstanding.